Anti-NY-ESO-1 TCR-T cell therapy

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-NY-ESO-1 TCR-T cell therapy
Drug Alias NameAnti-NY-ESO-1 TCR-T cell therapy(Medigene AG)CVTTCR-01CVT-TCR-01
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursMultiple MyelomaSarcoma, Synovial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedigene Ag
China Registration ClassN/A

Develop Information

Active CompaniesRoivant Sciences IncMedigene Ag
Inactive CompaniesN/A
Active IndicationsSolid tumoursMultiple MyelomaSarcoma, Synovial +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A